Replies to post #3265 on Arch Therapeutics Inc (ARTH)

[Shkreli cellmate]

According to their investor presentation (found on website)... slide 21 talks about their ip... mit expected expiry is 2026-2028... others assigned to arch expires soon after 2026 - 2034... (i think this presentation is from june 2016... i may be wrong)... Thats 10 - 14 years... and the product hasnt even been launched yet... im seeing that as limited timeline... Im pretty sure mgnt is trying to improve this...
Anyways from this... i can only fantasize so much (lets have a little fun)... lets say everything goes good and it takes 2 years from now to launch... giving us eh lets say 8 years to be conservative... addressing a potential $6b ww profit... though this takes time... lets say we capture 15% of that market... thats $900m revenue... 8 years.. about $7.2b potential... however, thats addressing every aspect of the market from heart surgery to nose bleeds to popping pimples... although we can play with the numbers all day long... that 8 years is the limiting factor... because of this... im sticking with $1 - 1.5b buyout is reasonable...